Burkholderia cepacia is a problematic pathogen that may spread among patients with cystic fibrosis (CF). One highly infectious CF strain that causes epidemics in both the United Kingdom and eastern Canada has been shown to possess both the cable pilin subunit gene (cblA) and a unique combination of insertion sequences. However, no genetic markers linking this strain type with other types epidemic at various centers have been identified. Using a randomly amplified polymorphic DNA (RAPD) typing scheme, we identified an apparently conserved 1.4-kb fragment in the DNA fingerprint of epidemic B. cepacia strains. Conservation of the DNA marker among epidemic strains was demonstrated by Southern hybridization, and its prevalence was assessed in a collection of chromosomal DNAs extracted from 627 isolates representative of 132 RAPD-defined B. cepacia strain types. The marker was specifically associated with seven epidemic CF strains, was absent among nonepidemic strains infecting individual patients with CF, and rare among strains recovered from the natural environment. Only one of the seven epidemic CF strain types possessed DNA homologous to cblA. The RAPD marker was designated the "B. cepacia epidemic strain marker" (BCESM). Sequence analysis of chromosomal DNA corresponding to the 1.4-kb RAPD marker revealed the presence of a putative open reading frame (ORF) with significant homology to several negative transcriptional regulators; the ORF was designated the "epidemic strain marker regulator," or esmR. The BCESM DNA is the first genetic marker that has been identified to be specifically associated with and conserved among several epidemic B. cepacia strains which infect multiple patients with CF.
Despite its evolving role in pulmonary infection in patients with cystic fibrosis (CF), very little is known about the pathogenesis of Burkholderia cepacia. Colonization of CF patients with B. cepacia has serious clinical implications since the organism is highly virulent in certain patients (30) and is resistant to multiple antibiotics (4) and because patient-to-patient spread of the bacterium, first documented in 1990 (17) , may occur. Evidence of the spread of B. cepacia strains among patients with CF and clustering of strain types at treatment centers has now been reported by a number of investigators (11, 18, 20) ; however, the factors which facilitate patient-topatient transmission of B. cepacia remain poorly understood. Transmission of B. cepacia among CF patients may be dependent on a number of risk factors including strain type (29, 31) , patient behavior and population (11) , use of contaminated therapeutic devices (15) , and CF treatment center practices (14) .
Few B. cepacia virulence factors have been characterized phenotypically or studied at the genetic level, and little is known about their role in pathogenesis during CF infection. B. cepacia may bind to and colonize respiratory epithelia in CF patients by mechanisms similar to those described for Pseudomonas aeruginosa (6) . Both organisms are generally motile and piliated and may adhere to the same disaccharide moiety present in many asialoglycolipids (21) . B. cepacia also secretes a number of extracellular virulence factors including siderophores, proteinases, hemolysins, and lipase (21) . Evasion of the immune system may also be enhanced by the intrinsic resistance of B. cepacia to nonoxidative killing (27) . B. cepacia recovered from CF patients whose clinical condition has undergone rapid deterioration binds to respiratory mucins with high affinity in vitro (23) , and adherence to buccal epithelial cells may occur via both pilus-mediated and non-pilus-mediated adhesive mechanisms (24) . To date, the only genetically characterized virulence factor associated with an epidemic B. cepacia strain type from CF patients is the cable pilus (10, 25, 29) . Tyler et al. (31) recently described a novel insertion sequence (IS), IS1356, which, in association with the element IS402, may also serve as a genetic marker for the epidemic B. cepacia strain type with a cable pilus; the pathogenic significance of these ISs remains to be determined (31) . These observations suggest that spread of the organism may also be linked to strain type; however, no genetic markers linking the cblA ϩ strain type and CF patient-derived strains epidemic at other treatment centers (18, 20) have been identified.
Using a PCR-based randomly amplified polymorphic DNA (RAPD) typing scheme, we typed 627 B. cepacia isolates recovered from CF patients and a variety of other sources (20) . During the latter study, a DNA band with a conserved size was observed in the RAPD fingerprints of B. cepacia strain types that were epidemic (infecting multiple CF patients at certain treatment centers) and that were presumed to be transmissible. The amplified band was absent from the RAPD fingerprints obtained from nonepidemic B. cepacia strain types which infected individual CF patients and rarely occurred in fingerprints for isolates recovered from the environment. The marker was designated the "B. cepacia epidemic strain marker" (BCESM) because of its association with B. cepacia strain types infecting multiple CF patients. In this report, we describe the identification of this novel B. cepacia DNA marker by RAPD analysis, the prevalence of homologous DNA among a collection of 627 B. cepacia isolates, and sequence analysis of the BCESM DNA. The prevalence of the cable pilin subunit gene (cblA) (25) among the same collection of isolates is also presented. Despite the widespread use of RAPD fingerprinting for typing various microorganisms, very few of the arbitrarily amplified DNA markers have been studied. This report provides the first characterization of a RAPD marker specifically amplified from epidemic strains of B. cepacia.
RAPD-PCR fragment was performed by dideoxy-termination PCR sequencing (CircumVent Thermal Cycle DNA sequencing kit; New England Biolabs, Mississauga, Ontario, Canada) by using the M13 forward and reverse primers. DNA sequences were analyzed manually on acrylamide gels (26) .
Specific 18-base PCR primers able to amplify the 1.4-kb BCESM band were designed from the sequence internal to that of RAPD primer 272 (see Results and Fig. 4 ). The sequences of the BCESM-specific primers were as follows (5Ј to 3Ј): BCESM 1, CCACGGACGTGACTAACA, and BCESM 2, CGTCCATCC GAACACGAT. PCR mixtures (25 l) containing 100 pmol of each primer, 20 ng of B. cepacia DNA, 250 M (each) deoxynucleoside triphosphate, 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 2 mM MgCl 2 , and 1 U of Taq polymerase (Canadian Life Technologies, Burlington, Ontario, Canada) were amplified on a Perkin-Elmer Cetus thermal cycler (model TC-1), as follows: 30 cycles of 1 min at 94ЊC, 1 min at 63ЊC, and 2 min at 72ЊC, followed by a final extension step at 72ЊC for 10 min. PCR products were analyzed by electrophoresis in 1.5% agarose gels as described previously (26) .
Dot blot hybridization of B. cepacia DNA with the PCR-derived BCESM probe. For dot blot hybridization analysis, approximately 1 g of DNA (dissolved in TE) from each of the 627 B. cepacia isolates was filtered under vacuum onto positively charged nylon membranes (Boehringer Mannheim) by using a 96-well dot-blot apparatus (Bio-Rad Laboratories). The BCESM DNA was amplified from B. cepacia C5424 by PCR with the specific primers described above and was simultaneously labelled with digoxigenin-11-uridine-5Ј-triphosphate (DIG-dUTP) according to the manufacturer's instructions (2a) . Dot blot filters were hybridized with the DIG-labelled BCESM DNA under the same conditions described above for the radiolabelled probe. After stringent washing, the filters were developed by chemiluminescence detection with Lumi-Phos 530 according to the manufacturer's instructions (2a) . After reaction with the BCESM probe, the filters were stripped of the probe by boiling them in 0.4 M NaOH for 10 min, and the filters were washed thoroughly with 2ϫ SSC prior to hybridization with the cable pilus gene probe (see below).
Dot blot hybridization of B. cepacia DNA with the cable pilin subunit gene probe. A full-length cable pilin subunit gene probe was amplified by PCR from B. cepacia C5424 by using the primers and conditions described by Sajjan et al. (25) . The 722-bp product was labelled during PCR with DIG-dUTP as described above. Prehybridization, hybridization, washing, and detection of the filters were carried out at high stringency exactly as described above for the BCESM probes.
Subcloning and sequence analysis of B. cepacia chromosomal BCESM region. Southern hybridization analysis of B. cepacia C5424 DNA localized the BCESM DNA to a 6.0-kb fragment that was generated by digestion of C5424 DNA with EcoRI and BamHI. Digested chromosomal DNA in this size range was purified following agarose gel electrophoresis as described above and was subcloned into E. coli DH5␣FЈ by using EcoRI-BamHI-digested pUC18 (26) . The resultant recombinant clones (approximately 2,000 colonies) were divided into six pools and were grown briefly, and then plasmid DNA was extracted by alkaline lysis (26) . Plasmid DNA pools were screened by PCR with the BCESM primers as described above. The BCESM DNA was amplified from two of the six pools, and one of these pools was retransformed into E. coli. PCR with the BCESM primers was then performed directly with individual colonies from this transformation, and two plasmid clones carrying the BCESM EcoRI-BamHI region were identified in the first 36 colonies screened. One of these plasmids was designated pTF1.2 and was used in all subsequent characterizations of the BCESM region.
After restriction mapping of the insert of pTF1.2, a 3.3-kb EcoRI-SalI fragment encoding the BCESM region was subcloned into pBluescript II SK Ϫ (Stratagene, La Jolla, Calif.), generating the plasmid pTF11. A series of unidirectional nested deletions of the insert of this plasmid were created using the Erase-a-Base System kit (Promega, Madison, Wis.). Fifteen of the resulting deletion clones were sequenced by automated PCR sequencing (Applied Biosystems 377 Automated DNA Sequencer and AmpliTaq DyeDeoxy Terminator Cycle Sequencing) with the T7 primer. Sequence data were assembled and analyzed by computer software (Lasergene for Windows; DNASTAR Inc., Madison, Wis.).
Sequence homology analysis. Computer-assisted searches of the GenBank, PIR, and SWISSPROT databases were performed by using either the BLAST or the BEAUTY program (1, 32) . Analysis of the putative EsmR protein was performed with the BLOCKS program (13) .
Nucleotide sequence accession number. The BCESM DNA sequence has been submitted to GenBank and assigned GenBank accession number U81966.
RESULTS
Identification of a RAPD marker of conserved size in epidemic B. cepacia strain types. In a separate study we reported a RAPD method that was able to discriminate B. cepacia isolates recovered from a variety of sources including CF infection (20) . Primary typing of B. cepacia was performed by RAPD analysis with primer 270; however, two additional RAPD primers, primers 208 and 272, were used to confirm the assignment of a given type (20) . The RAPD profiles amplified by primer 272 from strains representative of the first 14 RAPD types are shown in Fig. 1A . The fingerprint profiles of each strain type obtained with primer 272 were distinct, discriminated between strain types, and correlated with typing groups established with primer 270. However, a 1.4-kb DNA band amplified by primer 272 appeared to be conserved in the fingerprints of B. cepacia strain types for which there was evidence of patient-to-patient spread among CF patients in Vancouver (types 1, 2, 4, and 6; Fig. 1A ) and absent from the other nine nonepidemic CF strain types and one environmental strain type (Fig. 1A) .
B. cepacia type 1 was the predominant strain type colonizing 9 CF patients attending the pediatric clinic in Vancouver, type 2 was the epidemic strain type affecting more than 120 patients at treatment centers in the United Kingdom and across Canada, type 4 was the predominant strain type among patients attending the adult CF clinic in Vancouver, and type 6 B. cepacia infected a total of 5 pediatric CF patients in Vancouver (20) . Types 3, 5, 7, 8, 10, 12 , and 14 ( Fig. 1A) were each isolated from individual CF patients only (20) ; B. cepacia type 15 stably colonized one CF patient and was cultured on only one occasion from another CF patient who later became stably colonized with a type 6 strain (20) . Type 13 isolates were recovered from three CF patients in Manchester, United Kingdom (20) ; however, the 1.4-kb marker was not apparent in the fingerprint profile in Fig. 1A of the representative isolate amplified by RAPD analysis. Type 11 B. cepacia was isolated from soil (20) . Although the 1.4-kb marker was conserved in size among the majority of isolate types which infected multiple CF patients, because of the arbitrary nature of RAPD analyses, it may not have been homologous among the different strain types.
Conservation of the B. cepacia epidemic strain marker. Conservation of the BCESM DNA was demonstrated by the following experiments. The 1.4-kb DNA fragment was purified from the RAPD fingerprints of type 1, 2, 4, and 6 B. cepacia strains, and endonuclease cleavage of the DNA with HaeIII and PstI revealed identical RFLP profiles (data not shown). Conservation of the RFLP profile suggested that the chromosomal region amplified by primer 272 in these epidemic B. cepacia strain types was homologous. The absence of the 1.4-kb marker from the nonepidemic CF isolates and the environmental isolate examined (Fig. 1A) suggested that this chromosomal region was either missing or rearranged such that amplification by PCR was not possible. To further assess this chromosomal locus, both the randomly amplified DNA and the chromosomal DNA from B. cepacia were probed by Southern hybridization for the presence of sequences homologous to the 1.4-kb RAPD marker.
Southern hybridization analysis of the RAPD gel shown in Fig. 1A with a probe derived from the 1.4-kb RAPD marker of B. cepacia C5424 is shown in Fig. 1B . The 1.4-kb bands from all the B. cepacia isolates representative of the epidemic strain types except for type 13 (see below) hybridized to the probe (types 1, 2, 4, and 6); homologous DNA was not present in the RAPD fingerprints of the other strain types in Fig. 1A , indicating that the marker band was not amplified, even at a different size range, for these isolates. Southern hybridization of genomic DNA digested with PstI also revealed the presence of homologous 1-kb DNA in epidemic strain types 1, 2, 4, and 6 (data not shown); no homologous DNA at any size range was detected in the nonepidemic strain types examined (data not shown). Examination of restriction enzyme-digested genomic DNA from B. cepacia C5424 by Southern hybridization localized the marker DNA to a 6-kb EcoRI-BamHI chromosomal fragment (data not shown). Because the 1.4-kb RAPD fragment had been localized to a chromosomal locus and was truly absent from the nonepidemic CF isolates examined, the marker was designated BCESM and was cloned in E. coli for further characterization (see below).
Subcloning of BCESM RAPD band and design of specific PCR primers. In order to develop a specific PCR probe for the BCESM region and to subsequently facilitate cloning of the chromosomally encoded marker region, the 1.4-kb RAPD-PCR marker amplified from strain C5424 was cloned in E. coli, generating plasmid pBC57 (see Materials and Methods). Sequence analysis of each end of the cloned 1.4-kb PCR fragment enabled the design of specific PCR primers by using the sequences internal to that of RAPD primer 272 which formed the ends of the amplified marker (see Fig. 4 ). These specific 18-base PCR primers, BCESM 1 and BCESM 2 (see Materials and Methods), enabled the 1.4-kb marker to be amplified from the chromosomal DNAs of positive B. cepacia strains (Fig. 2) .
Amplification of the BCESM by RAPD analysis from strains of types 1, 2, 4, and 6 had been demonstrated by Southern hybridization (Fig. 1) , and these strain types were also positive for the specific PCR marker (Fig. 2) . Type 13 isolates, which lacked the marker by RAPD analysis, but which had the characteristics of an epidemic B. cepacia strain, were found to amplify a single fragment by specific PCR (Fig. 2) . The size of the marker amplified from type 13 isolates was slightly higher than that of the other epidemic types; however, the RFLP profile generated by digestion with HaeIII was conserved ( strain type at a treatment center in Cleveland, Ohio (18) , and type 40, an epidemic B. cepacia CF strain from a center in Australia (20) , were also positive for the marker (Fig. 2) . No product was observed after amplification of DNA from the nonepidemic CF isolates (amplification of the DNA of a type 3 isolate is shown in Fig. 2) . The BCESM DNA amplified by specific PCR shared the same HaeIII-derived and PstI-derived RFLP pattern as the RAPD marker (Fig. 2) and also hybridized to the RAPD-derived fragment (data not shown), demonstrating that both types of probe detected the same chromosomal sequence.
The specific PCR primers also facilitated the cloning of chromosomal BCESM DNA from B. cepacia C5424 into E. coli with the vector pUC18 (26) (see Materials and Methods).
Prevalence of BCESM DNA among B. cepacia isolates recovered from a variety of sources. To assess the prevalence of the BCESM region among B. cepacia isolates, total genomic DNA from 627 strains, previously assessed by RAPD analysis (20) , was examined by DNA dot blot hybridization with the specific PCR-derived BCESM probe from strain C5424 (Fig. 2 , DNA sample B57); the results are summarized in Table 1 . Hybridization was carried out at high stringency in order to identify sequences homologous to the BCESM probe (see Materials and Methods), and the signals obtained from the DNAs of control strains known to be positive for the marker were strong (Fig. 3 , DNA samples B16, B20, B26, and B57). The BCESM PCR probe hybridized with the DNAs of all 128 CF isolates which belonged to the epidemic RAPD types 1, 4, 6, and 13. Of the three other B. cepacia types which infected multiple CF patients (types 2, 17, and 40), DNAs from a total of five B. cepacia isolates belonging to these fingerprint types did not hybridize to the marker (Table 1) ; two type 2, one type 17, and two type 40 isolates were negative for BCESM DNA (Table 1) .
Of the remaining CF isolates examined, 101 were recovered from a total of 57 individual CF patients and were not shared by another patient (nonepidemic CF patient-derived and unique CF patient-derived types; Table 1 ) (20) . Three of the types classified as nonepidemic were recovered from two CF patients. Infection of the two CF patients with type 15 B. cepacia isolates was transient (20) . Type 23 and type 35 B. cepacia isolates were each recovered from two CF patients at treatment centers in Oklahoma City and Edinburgh, United Kingdom, respectively; no further isolates of these types were found in the collection to support their categorization as epidemic (20) . Among the isolates recovered from patients without CF, 20 of 44 isolates (45%) possessed homologous DNA (Table 1) . Only 5 of the 58 isolates (8.6%) recovered from environmental sources harbored DNA homologous to the BCESM probe (Table 1) .
Total genomic DNAs from the following organisms did not hybridize to the BCESM probe (n indicates the number of strains tested): Agrobacterium radiobacter (n ϭ 1), Alcaligenes faecalis (n ϭ 1), Alcaligenes xylosoxidans (n ϭ 5), Burkholderia gladioli (n ϭ 13), Candida spp. (n ϭ 1), Comamonas acidovorans (n ϭ 5), Enterobacter agglomerans (n ϭ 1), E. coli (n ϭ 2), Chryseobacterium (Flavobacterium) meningosepticum (n ϭ 1), P. aeruginosa (n ϭ 15), Mycobacterium tuberculosis (n ϭ 2), and Stenotrophomonas (Xanthomonas) maltophilia (n ϭ 4) (data not shown). Correlation of the BCESM marker and B. cepacia RAPD type. Since the majority of CF isolates in our collection belonged to the epidemic CF RAPD types 1, 2, 4, 6, 13, 17, and 40 (417 of 525 CF isolates; Table 1), the bias in total numbers may have skewed the distribution of the BCESM probe. However, because all 627 isolates had been typed by RAPD analysis, the distribution of the BCESM DNA was also examined by strain type; these data are summarized in Table 2 .
In total, 78 distinct RAPD types of B. cepacia were recovered from CF patients, and 15 of these possessed BCESM DNA (Table 2) . Of the positive strain types, seven types were epidemic and infected multiple CF patients, as explained e The totals were calculated after subtraction of the six strain types recovered from more than one source, which are described in footnotes b, c, and d.
above; the eight remaining positive types had a unique fingerprint, and each was recovered from an individual CF patient in disparate geographical locations (20) . Therefore, in contrast to the data obtained from the total number of isolates, the majority of CF strain types lacked BCESM DNA. Sixty of the negative CF strain types (10 nonepidemic CF types and 50 unique CF types; Table 2 ) were each recovered from individual CF patients, and no evidence of spread of these strain types was apparent. Of the three remaining BCESM-negative CF strain types (types 15, 23, and 35), evidence of patient-topatient spread was not substantiated by further data (20) . Among the B. cepacia strain types recovered from patients without CF, 7 of a total of 24 types possessed the marker ( Table 2 ). Of the 36 strain types recovered from the environment, 4 possessed DNA homologous to the BCESM probe. Two of these BCESM-positive environmental strain types were isolated from hospital environments (types 2 and 26; Table 2 ) (20) . The remaining two BCESM-positive types were recovered from the natural environment (20) .
Prevalence of the cable pilus gene, cblA. The DNAs from all 627 B. cepacia isolates were also hybridized with the cable pilus gene probe (cblA) (25) . Dot blot hybridization results for DNA from the first 60 isolates are presented in Fig. 3B . In total, 272 of the 627 isolates tested possessed DNA homologous to the cblA gene, and of these, 267 (98%) belonged to the same strain lineage, RAPD type 2, the major CF RAPD strain type (20) representative of this epidemic lineage (29, 31) . None of the other epidemic CF strain types or nonepidemic CF strain types possessed DNA homologous to cblA. One CF isolate with a unique RAPD fingerprint, recovered from a patient in Oklahoma, hybridized with the cblA probe; DNA from this isolate did not hybridize with the BCESM probe ( Table 2 ). The cblA gene was present in B. cepacia ATCC 35130, an environmental isolate, and another environmental isolate from Mexico which shared the same RAPD type (type 31) as ATCC 35130 (Table  2) . Two further environmental isolates from distinct geographical sources (the United States and the United Kingdom) with unique RAPD fingerprints possessed cable pilus DNA; both of these lacked DNA homologous to the BCESM probe. None of the clinical isolate types recovered from patients without CF carried the cable pilus gene (Table 2 ). In total, only 6 of the 132 RAPD-defined B. cepacia strain types possessed DNA homologous to the cable pilin subunit gene (Table 2) .
Nucleotide sequence of the BCESM DNA. A 6.0-kb chromosomal DNA fragment from B. cepacia C5424 (B57) encoding BCESM was cloned in E. coli; the nucleotide sequence from 3.4 kb of DNA encompassing the BCESM probe was determined (see Materials and Methods). The features of the 1,600 bp of DNA spanning the BCESM marker are shown in Fig. 4A , and the corresponding nucleotide sequence is shown in Fig.  4B .
Sequences identical to those of PCR primers BCESM 1 and BCESM 2 were found 1,419 bp apart, and recognition sites for the endonuclease PstI, used to generate the first RAPD-derived 1.0-kb probe, were encoded 1,022 bp apart within the 1,419-bp PCR product (Fig. 4) . The sequence of RAPD primer 272 (5Ј-AGCGGGCCAA-3Ј), which originally amplified the BCESM DNA, was only partially matched upstream and downstream of the sequences encoding the specific BCESM PCR primers (Fig. 4A) . A total of 8 bp upstream and 9 bp downstream were matched at the 3Ј terminus of the primer binding site (Fig. 4B) . Although this level of homology was sufficient for amplification of the marker from most of the epidemic strain types under the low-stringency RAPD-PCR conditions, the degree of mismatch may explain the inability of RAPD analysis to amplify the marker from type 13 strains, which may contain further sequence differences in this region ( Fig. 1 and 3) .
Sequence homology analysis of the BCESM DNA. Sequence analysis of the marker revealed the presence of a 834-bp open reading frame (ORF) encoding a putative 277-amino-acid protein which was internal to the 1.4-kb BCESM marker (Fig. 4) . Comparison of the sequence of this ORF with nucleotide and protein sequences present in the standard databases demonstrated significant homology to several negative transcriptional regulators. The putative ORF was designated the "epidemic strain marker regulator," or esmR, because of the homology to negative transcriptional regulators. The putative EsmR protein possessed the highest similarity (of 50 to 60% over several domains) with YhcK, a hypothetical transcriptional regulator from E. coli; UxuR, a regulator of glucuronate metabolism in E. coli (2, 3) ; PdhR, a negative transcriptional regulator of the pyruvate dehydrogenase complex of E. coli (28) ; and LldR, a putative regulator gene of E. coli involved in lactate dehydrogenase production (8) . The region of highest similarity occurred in the N-terminal domains of all of the homologs, in which a helix-turn-helix domain was present. The putative EsmR protein also possessed a helix-turn-helix domain (Fig.  4B) , suggesting that it is involved in a regulatory capacity in B. cepacia. Thus, EsmR likely belongs to the GntR family of bacterial regulatory proteins (12) .
DISCUSSION

B. cepacia infection in patients with CF is problematic.
Knowledge of the risk factors leading to transmission and the features of B. cepacia which may enable it to spread from one CF patient to another is limited. We have identified by RAPD analysis a novel region of DNA specifically associated with epidemic strain types of B. cepacia which infect multiple CF patients at various treatment centers. The identification of this marker by RAPD analysis illustrates the versatility of the PCRbased technique for the genomic characterization of organisms for which genetic knowledge is limited. Identification of a putative ORF within the marker DNA sequence, which shares homology with a family of negative transcriptional regulators, may provide insights into the virulence factors responsible for patient-to-patient spread, aid in the identification of problematic strain types, and assist in the diagnosis and management of B. cepacia infections in patients with CF.
To date, only the cable pilus and mesh pilus virulence factors have been linked with epidemically transmitted CF isolates of B. cepacia (10, 29) . Goldstein et al. (10) categorized B. cepacia CF isolates as "epidemically transmitted" and "nonepidemically" or "low-level transmissibility" isolates from their epidemiological backgrounds. Strains possessing the cable and mesh pilus types were categorized with "epidemically transmitted" CF isolates (10) . Such division of B. cepacia strains must be approached with caution since the risk factors for B. cepacia transmission and the pathogenesis of the organism are not fully understood. Tyler et al. (31) recently described IS markers which were also specifically associated with cable pilus-linked epidemic lineage. The BCESM DNA identified in this study is predominantly associated with strains of B. cepacia that infect multiple CF patients at various treatment centers and that by definition were epidemic at each center. However, since the available epidemiological data on the colonized patients was limited, assumptions on the exact mode and frequency of transmission of these epidemic B. cepacia strain types cannot be accurately made.
The B. cepacia epidemic strain types infecting multiple CF patients attending the Vancouver, Cleveland, Manchester, and Australian treatment centers all lacked the cable pilus gene, but did possess DNA homologous to the BCESM (types 1, 4, 6, 13, 17, and 40; Table 1 ). The absence of the cable pilus marker in all the other epidemic strain types examined in this study is in contrast to the results of Sun et al. (29) , whose studies highlighted the spread of only one strain type among CF patients and promoted the fact that the cblA DNA is a useful marker for infectious strain types. Our data demonstrate The corresponding 1,600-bp nucleotide sequence and amino acid translation of the putative ORF. Nucleotides matching RAPD primer 272 are indicated with a dotted line, and the sequences of the BCESM PCR primers are underlined. The amino acid translation of the putative EsmR protein is indicated by boldface type beneath the nucleotide sequence. The underlined region of EsmR corresponds to the putative helix-turn-helix domain homologous with the helix-turn-helix domains of a number of negative transcriptional regulators (12) . that all B. cepacia colonization among patients with CF is of major concern and that strain types other than those with the cblA ϩ lineage should not be considered less of a problem just because the cable pilus-carrying strain has been designated "highly infectious" (10, 30) . Although the cblA marker is associated with the most prevalent B. cepacia CF strain type in the United Kingdom and North America (RAPD type 2; Tables 1 and 2) (20) , it was present in only 6 of the 132 RAPDdefined strain types in the collection of 627 isolates examined (Table 2) ; of these 6 cblA ϩ types, only 1 was an epidemic CF strain type (type 2), as defined by our collection. Interestingly, B. cepacia RAPD type 2 was the only strain type in the entire collection possessing both the cable pilin subunit gene and the BCESM DNA. Since the combination of IS1356 and IS402 is also associated with this infectious strain type (31) , these data suggest virulence factors linked with this unique combination of genetic markers may contribute to the striking prevalence of this lineage within the CF patient population.
DNA homologous to the BCESM probe was absent from 5 of 417 isolates belonging to epidemic CF types, suggesting that the region may be subject to some instability. Multiple replicons are present in the genome of B. cepacia (7, 22) , and therefore, it is possible that the BCESM region may be encoded on a replicon which may be unstable in some transmissible CF isolates. There was no correlation with the BCESM marker and the presence of a plasmid when conventional alkaline lysis (26) was used as a means of DNA preparation (data not shown); however, this procedure is inefficient for the purification of plasmids greater than 50 kb in size (26) . The genome of B. cepacia may also be quite plastic due to large numbers of ISs present (9) , and specific ISs have recently been linked to the cblA epidemic strain type (31) . No sequences homologous to IS elements present in databases were found on the sequence of the BCESM region; however, if IS elements flank the BCESM region that we have characterized, this may contribute to its instability in vitro in certain strain types.
The majority of CF strain types lacked the BCESM, and hence, the DNA cannot be considered a universal marker for the ability of B. cepacia to colonize and cause infection in patients with CF. However, the specific association of the BCESM DNA with strain types which infect multiple CF patients suggests that it can be used to identify strain types which have a high capacity to spread among CF patients and become epidemic at a given treatment center. For example, type 6 B. cepacia, a BCESM-positive strain, colonized only one CF patient at the treatment center in Vancouver for 6 years (20) . In the seventh year of study, this strain type spread to two other pediatric CF patients and subsequently to more patients to infect a total of five CF patients attending the treatment center (20) . Because of this specific association with strain transmission and not colonization per se, the BCESM DNA may mark a region of the B. cepacia genome which encodes virulence factors or regulators which play a role in strain transmissibility. The role of the putative EsmR protein encoded on the 1.4-kb BCESM DNA remains to be determined. Significant homology to the GntR family of bacterial regulatory proteins and possession of a DNA-binding helix-turn-helix motif (12) suggest that it may play a regulatory role in B. cepacia; however, the ORF's authenticity and regulatory targets remain to be determined.
Phenotypic examination of B. cepacia strains recovered from the natural environment has indicated that they are markedly different from epidemic strains associated with pulmonary infection in CF patients (5) , and multilocus enzyme electrophoresis has also shown that environmental isolates produce electrophoretic profiles that are in general distinct from those of CF isolates (16) . The low prevalence of the BCESM DNA among B. cepacia strains recovered from the natural environment (2 of 36 types examined; Table 2) suggests that in general these strain types are also genetically distinct from the strains which infect multiple CF patients. Identification of the BCESM DNA region, which is the first genetic marker conserved among several epidemic types of B. cepacia, suggests that phenotypic factors which are associated with this DNA but which are absent from isolates present in the natural environment may be important for the spread of this organism among patients with CF.
The B. cepacia BCESM DNA did not hybridize to DNA from a wide variety of other microorganisms present in sputum, and the clear distinction between positive and negative B. cepacia strains suggests that DNA probes based on this region may be useful clinically for the identification of potentially problematic strain types. The prevalence of the B. cepacia BCESM marker will need to be evaluated in other CF treatment centers where transmissible isolates are thought to be present. However, on the basis of the results presented in this report, the BCESM probe is the first genetic link identified between several epidemic strain types, and it may serve as a putative marker for the presence of strains of B. cepacia with the potential for spread among patients with CF.
